A report of two long-surviving cases of pulmonary lymphangioleiomyomatosis and the response to progesterone therapy

Two cases of pulmonary lymphangioleiomyomatosis, with survival between 12 and 28 years are described. Both were treated with medroxyprogesterone acetate with a slight initial improvement in both lung function and exercise tolerance, and no further deterioration during the period of follow-up of 10–2...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of diseases of the chest Vol. 79; no. 4; pp. 400 - 406
Main Authors Sawicka, E.H., Morris, A.J.R.
Format Journal Article
LanguageEnglish
Published London Elsevier Ltd 1985
Baillière Tindall
Subjects
Adult
Biological and medical sciences
Female
Follow-Up Studies
Humans
Lung - physiopathology
Lung Neoplasms - drug therapy
Lung Neoplasms - physiopathology
Lymphangiomyoma - drug therapy
Lymphangiomyoma - physiopathology
Lymphoproliferative Disorders - drug therapy
Medical sciences
Medroxyprogesterone - analogs & derivatives
Medroxyprogesterone - therapeutic use
Medroxyprogesterone Acetate
Pharmacology. Drug treatments
Respiratory Function Tests
Respiratory system
Human
Chemotherapy
Respiratory disease
Leiomyomata
Lung
Progesterone
Lymphangioma
Online AccessGet full text

Cover

More Information
Summary:Two cases of pulmonary lymphangioleiomyomatosis, with survival between 12 and 28 years are described. Both were treated with medroxyprogesterone acetate with a slight initial improvement in both lung function and exercise tolerance, and no further deterioration during the period of follow-up of 10–20 months. The results are discussed and other reports of hormonal treatment of this rare condition are reviewed.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0007-0971
1878-2426
DOI:10.1016/0007-0971(85)90077-4